{
    "nctId": "NCT06065059",
    "briefTitle": "Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors",
    "officialTitle": "Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "To determine dosing for TNG348 alone and in combination (Phase 1 only)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Is \u226518 years of age at the time of signature of the main study ICF.\n* Has ECOG performance status of 0 or 1.\n* Has advanced or metastatic solid tumor with measurable disease based on RECIST v1.1.\n* All participants must have documented BRCA 1/2 mutant or other HRD+ in solid tumor, which is identified through a validated sequencing test\n* Adequate organ and bone marrow function per local labs\n* Negative serum pregnancy test result at screening\n* Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n* Known allergies, hypersensitivity, or intolerance to TNG348, olaparib or its excipients\n* Uncontrolled intercurrent illness that will limit compliance with the study requirements\n* Currently participating in or has planned participation in a study of another investigational agent or device\n* Impairment of GI function or disease that may significantly alter the absorption of study drug\n* Active prior or concurrent malignancy.\n* Central nervous system metastases associated with progressive neurological symptoms\n* Participant with MDS\n* Clinically relevant cardiovascular disease\n* Participant with known active or chronic infection\n* A female patient who is pregnant or lactating",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}